Skip to content
Open access

Peripheral blood transcriptomic signature is associated with cognitive impairment and freezing of gait in Parkinson’s disease: a data-driven approach

Aug 2026 · npj Parkinson's Disease · Vol 12 · 0 citations · 44 references
Medicine

TL;DR

It is demonstrated that peripheral blood transcriptomic signatures capture aspects of PD pathophysiology that are not fully explained by nigrostriatal dopaminergic degeneration alone, serving as potential prognostic biomarkers for cognitive impairment and FOG.

Abstract

Parkinson’s disease (PD) is a heterogeneous neurodegenerative disorder with variable long-term outcomes. Blood-based biomarkers for prognostic prediction remain underdeveloped. We aimed to develop a peripheral blood transcriptomic signature for predicting long-term complications in PD using unsupervised data-driven methods. Using RNA sequencing data from 541 PD patients and 180 healthy controls from the Parkinson’s Progression Markers Initiative (PPMI), we employed weighted gene correlation network analysis (WGCNA) to identify disease-associated gene modules. Contrastive principal component analysis was applied to derive a pseudo-temporal (PT) trajectory score reflecting molecular disease progression. The prognostic value of PT scores was assessed through Cox regression for cognitive impairment, freezing of gait (FOG), wearing-off, and levodopa-induced dyskinesia. WGCNA identified two PD-associated co-expression modules enriched for immune/inflammatory pathways. PT scores derived from these modules showed significant correlations with cognitive, autonomic, and axial motor symptoms. In multivariable Cox regression, higher PT scores independently predicted cognitive impairment (HR = 7.31, P = 0.002) and FOG (HR = 3.43, P < 0.001), but not predominantly dopaminergic motor complications. These findings demonstrate that peripheral blood transcriptomic signatures capture aspects of PD pathophysiology that are not fully explained by nigrostriatal dopaminergic degeneration alone, serving as potential prognostic biomarkers for cognitive impairment and FOG.

Read PDF

Similar papers

Oct 2026

Identification of a shared blood-brain transcriptomic signature in Parkinson's disease using bioinformatic and network pharmacology approaches.

Parkinsons disease, characterized by the aggregation of alpha-synuclein is a complex neurodegenerative disorder with the fastest global prevalence growth. The identification of shared genes expressed in both blood and brain of Parkinson's disease patients improves the knowledge on peripheral pathophysiology of the dise...

Hafsa Mohammad, Akanksha Singh, Dipika Bansal · 0 citations
Open access Sep 2026

Proteo-metabolomic integration identifies stage-specific candidate biomarkers for Parkinson’s disease

An integrated multi-omics approach provides a robust framework for stage-specific PD monitoring and potential clinical deployment using multi-omics machine learning to identify biofluid-specific signatures and evaluated predictive performance.

A. Galal, Ahmed Moustafa, Mohamed Salama · 0 citations
Open access Sep 2026

Prediction of cognitive impairment in Parkinson’s disease using TabPFN: an integrative analysis of clinical data, longitudinal trajectories, and lipidomics

Cognitive impairment is a common and disabling non-motor manifestation of Parkinson’s disease (PD). Early identification of patients at high risk remains challenging, and the metabolic mechanisms underlying cognitive decline are not fully understood. We conducted a retrospective cohort study including PD pat...

Zi-Kai Zhou, Jie Liu, Li-Juan Wang et al. · 0 citations
Open access Sep 2026

A neuroimmune-enriched multibiofluid proteomic index associated with cognitive-motor progression in early Parkinson’s disease: a longitudinal PPMI cohort study

NEMPI is interpreted as an abundance-based, neuroimmune-enriched, multibiofluid proteomic composite associated with broad cognitive-motor progression, not as a patient-level prediction tool, clinical threshold, cognition-specific biomarker, or causal mechanism.

Hao Wang, Guo-Qing Wu, Deng-Ke Zhang et al. · 0 citations
Aug 2026

Transcriptome-wide association analysis of Alzheimer’s disease: construction and clinical validation of transcriptomic risk scores

The AD-specific transcriptomic risk scores (TRSs) developed in this study shows promising clinical utility in AD diagnosis, differential diagnosis, and risk prediction, providing valuable translational medical evidence for early screening and precision prevention of Alzheimer's disease.

Peng-Fei Zhang, Zhongqian Juan, Jia-Lin Han et al. · 0 citations
Open access Sep 2026

Lysosomal Expression Profile in Plasma Associates with Disease Severity in Parkinson's Disease.

These findings support the use of pathway-specific biomarkers for improving PD diagnostics and monitoring disease progression and support the use of pathway-specific biomarkers for improving PD diagnostics and monitoring disease progression.

Janna van Wetering, M. V. van Ingen, Evelien Timmermans et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.